Poolbeg Pharma: trial green-lit, billion-dollar market - and data due this summer episode artwork

EPISODE · Apr 15, 2026 · 5 MIN

Poolbeg Pharma: trial green-lit, billion-dollar market - and data due this summer

from Proactive - Interviews for investors · host Proactive Investors

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001. Full MHRA clearance has been secured, clearing the final regulatory hurdle before patient screening begins across six UK sites. Interim data from the trial, which targets cytokine release syndrome — a serious complication of cancer immunotherapies — is expected this summer. On the commercial side, independent US payer research confirms multi-billion-dollar peak sales potential, with insurers recognising the significant cost burden CRS places on healthcare systems. The findings are expected to strengthen Poolbeg's hand in upcoming partnership discussions. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #PoolbegPharma #POLB001 #Biotech #ClinicalTrials #CRS #PharmaNews #DrugDevelopment #HealthcareInnovation #Investing #Biopharma #MHRA #CytokineReleaseSyndrome #LifeSciences

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001. Full MHRA clearance has been secured, clearing the final regulatory hurdle before patient screening begins across six UK sites. Interim data from the trial, which targets cytokine release syndrome — a serious complication of cancer immunotherapies — is expected this summer. On the commercial side, independent US payer research confirms multi-billion-dollar peak sales potential, with insurers recognising the significant cost burden CRS places on healthcare systems. The findings are expected to strengthen Poolbeg's hand in upcoming partnership discussions. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #PoolbegPharma #POLB001 #Biotech #ClinicalTrials #CRS #PharmaNews #DrugDevelopment #HealthcareInnovation #Investing #Biopharma #MHRA #CytokineReleaseSyndrome #LifeSciences

NOW PLAYING

Poolbeg Pharma: trial green-lit, billion-dollar market - and data due this summer

0:00 5:38

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Proactive - Interviews for investors?

This episode is 5 minutes long.

When was this Proactive - Interviews for investors episode published?

This episode was published on April 15, 2026.

What is this episode about?

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss a pivotal moment for the company's lead asset, POLB 001. Full MHRA clearance has been...

Can I download this Proactive - Interviews for investors episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!